SavedAdd your journal

Journals / Epilepsi / 2019 / Cilt: 25 - Sayı: 2

Current Views on the Use of Valproic Acid in Women

Kadınlarda Valproik Asit Kullanımında Güncel Gelişmeler

Kezban ASLAN KARA
Hacer BOZDEMİR
Journal
Epilepsi
Pages
45–50
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review was to assess the current status of recommendations for the use of VPA according to international drug commissions and other recent reports.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Valproic acid (VPA) is one of the most frequently prescribed antiepileptic drugs for idiopathic generalized epilepsy, chronic or migraine headache, and bipolar disorder; however concerns about teratogenic effects have resulted in limited usage of the drug in women of childbearing potential.
📊
Key Findings & Data:Valproic acid (VPA) is one of the most frequently prescribed antiepileptic drugs for idiopathic generalized epilepsy, chronic or migraine headache, and bipolar disorder; however concerns about teratogenic effects have resulted in limited usage of the drug in women of childbearing potential.
💡
Conclusion & Impact:The aim of this review was to assess the current status of recommendations for the use of VPA according to international drug commissions and other recent reports.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Valproic acid (VPA) is one of the most frequently prescribed antiepileptic drugs for idiopathic generalized epilepsy, chronic or migraine headache, and bipolar disorder; however concerns about teratogenic effects have resulted in limited usage of the drug in women of childbearing potential. The aim of this review was to assess the current status of recommendations for the use of VPA according to international drug commissions and other recent reports.

Özet

alproik asit (VPA), jeneralize epilepsiler, baş ağrısı ve bipolar bozuklukta sık kullanılan bir ilaçtır. Ancak VPA’nın majör teratojenik etkisinin diğer antiepileptik ilaçlara göre daha yüksek olması nedeni ile son yıllarda üreme çağındaki kadınlarda bu ilacın kullanımının sınırlandırılması gerektiği kanısını oluşturmuştur. Bu yazı VPA’nın kadınlarda kullanılması ile ilişkili olarak, uluslararası ilaç komisyonlar tarafından yayımlanan güncel raporlar ve son dönemde VPA’nın epilepsi tedavisindeki konumu hakkında bilgi vermek üzere derlenmiştir.

🔖

Cite This Article

KARA, K. A., BOZDEMİR, H. (2019). Current Views on the Use of Valproic Acid in Women. Epilepsi, Cilt: 25 - Sayı: 2, 45–50. https://ajindex.com/articles/150777

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Aldenkamp A, Vigevano F, Arzimanoglou A, Covanis A. Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurol Scand Suppl 2006;184:1–13. Löscher W. The pharmacology of valproate In: Valprota. 1st ed.Berlin: Birkhäuser Basel; 1999. p. 1–3. Kupferberg HJ. Sodium valproate. In: Glaser GH, Penry JK, Woodbury DM, editors. Antiepileptic drugs: Mechanism ofaction. New York: Raven Press; 1980. p. 643–54.
  2. Löscher W, Frey HH. Effect of convulsant and anticonvulsant agents on level and metabolism of gamma-aminobutyric acid in mouse brain. Naunyn Schmiedebergs Arch Pharmacol 1977;296(3):263–9.
  3. Czuczwar SJ, Frey HH, Löscher W. Antagonism of N-methyl-D,Laspartic acid-induced convulsions by antiepileptic drugs and other agents. Eur J Pharmacol 1985;108(3):273–80.
  4. Löscher W, Meldrum BS. Evaluation of anticonvulsant drugs in genetic animal models of epilepsy. Fed Proc 1984;43(2):276–84.
  5. Hönack D, Löscher W. Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res 1992;13(3):215–21.
  6. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36 Suppl 2:S2–12. Gerstner T, Bell N, König S. Oral valproic acid for epilepsy--longterm experience in therapy and side effects. Expert Opin Pharmacother 2008;9(2):285–92. Schachter SC. Review of the mechanisms of action of antiepileptic drugs. Drugs 1995;4(6):469–77.
  7. Tang Y, Glauser TA, Gilbert DL, Hershey AD, Privitera MD, Ficker DM, et al. Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol Scand 2004;109(3):159–68.
  8. Levy RH, Shen DD. Valproic acid: absorption, distribution, and excretion. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press; 1995. p. 605–20
  9. Nau H, Krauer B. Serum protein binding of valproic acid in fetus-mother pairs throughout pregnancy: correlation with oxytocin administration and albumin and free fatty acid concentrations. J Clin Pharmacol 1986;26(3):215–21. Rothrock JF. Clinical studies of valproate for migraine prophylaxis. Cephalalgia 1997;17(2):81–3.
  10. Deltito JA, Levitan J, Damore J, Hajal F, Zambenedetti M. Naturalistic experience with the use of divalproex sodium on an inpatient unit for adolescent psychiatric patients. Acta Psychiatr Scand 1998;97(3):236–40. Schmidt D. Adverse effects of valproate. Epilepsia 1984;25 Suppl 1:S44–9. Nau H. Teratogenic valproic acid concentrati